Results 231 to 240 of about 158,490 (343)

Chronic gastritis.

Japanese Journal of Medicine, 1985
openaire   +5 more sources

LIF/LIFR Signaling in Gastric Cancer: A Double‐Edged Sword in Tumor Progression and Therapeutic Resistance

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Gastric cancer (GC) remains a major cause of cancer‐related mortality worldwide, driven by late‐stage diagnoses and poor survival outcomes. Leukemia inhibitory factor (LIF) and leukemia inhibitory factor receptor (LIFR) are increasingly recognized as critical players in GC pathophysiology, though their exact roles are not fully understood. LIF,
Daniel Park, Kyung‐Il Kim, Yate‐Ching Yuan, Pranati Shah, Hannah Zhong, Yu‐Han Chen, Sharity Ondrejik, Ellen Choi, Sofia Guzman, Vitor Goes, Christiana Crook, Wenqi Wang, Dani Ran Castillo, Daneng Li   +13 more
wiley   +1 more source

A Three-Way Comparison of Nodular Lesions in H. pylori-Induced Gastritis, Non-Helicobacter pylori Helicobacter (NHPH)-Induced Gastritis, and NHPH-Induced MALT Lymphoma Reveals Their Distinct Endoscopic Predictors: Distribution for Bacterial Etiology and Morphology for Malignancy. [PDF]

Helicobacter
Kitadai Y, Takigawa H, Nagao A, Shimizu D, Ariyoshi M, Takasago T, Tsuboi A, Tanaka H, Yamashita K, Hiyama Y, Kishida Y, Urabe Y, Ishikawa A, Kuwai T, Oka S.   +14 more
europepmc   +1 more source

Chronic Fibrosing Gastritis Associated with Ollulanus tricuspis in a Cat [PDF]

, 1982
A. M. Hargis, David J. Prieur, Jim Blanchard, Francisco J. Trigo‐Tavera   +3 more
openalex   +1 more source

Elucidating the Anticancer Mechanisms of Tetrahydroxycurcumin: A Comprehensive Review of Preclinical Studies

Food Science &Nutrition, Volume 13, Issue 11, November 2025.
Tetrahydroxycurcumin is an attractive multifunctional compound in cancer‐driven therapeutics. Its anticancer potential in modulating a wide range of oncogenic signaling networks, combined with its dual properties as an antioxidant and anti‐inflammatory agent, highlights its potential to become a transformative anticancer drug.
Muhammad Shahbaz, Ushna Momal, Hagar M. Mohamed, Asfa Perween, Hammad Naeem, Muhammad Imran, Muzzamal Hussain, Gamal A. Mohamed, Sabrin R. M. Ibrahim, Tadesse Fenta Yehuala, Suliman A. Alsagaby, Waleed Al Abdulmonem, Mohamed A. Abdelgawad, Ehab M. Mostafa, Samy Selim   +14 more
wiley   +1 more source

Characteristics of Gastric Endoscopic and Histopathological Findings in the South and Southeast Asian Populations. [PDF]

JGH Open
Sugimoto M, Matsuhisa T, Aftab H, Limpakan S, Sharma Dhakal SK, Sang K, Htet K, Yee TT, Yamaoka Y.   +8 more
europepmc   +1 more source

Hemorrhagic gastritis

, 1969
I. L. Pevtsov
openalex   +2 more sources

Difference in chromatin sensitivity to heparin of chronic atrophic gastritis, of carcinoma‐free and carcinoma‐bearing stomach in comparison with normal gastric mucosa and gastric carcinoma as revealed by flow cytometry [PDF]

, 1983
H. Weiß, U. Heinz, Herbert Gütz, W. Schälicke   +3 more
openalex   +1 more source

Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma

Hematological Oncology, Volume 43, Issue 6, November 2025.
ABSTRACT Patients with Hodgkin lymphoma (HL) or peripheral T‐cell lymphoma (PTCL) who relapse after high‐dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab‐vedotin (BV) is a CD30‐targeting antibody‐drug‐conjugate (ADC) used in first‐line‐, salvage‐, and maintenance‐therapy of HL, as well as first‐line‐ and salvage‐therapy of PTCL. In phase I
Christian Rausch, Ulrike Bacher, Manuela Rabaglio, Corinne Vorburger, Anke Klingenberg, Yara Banz, Michael Daskalakis, Thomas Pabst   +7 more
wiley   +1 more source

Gastric devascularization in a neonate with massive upper GI bleeding: a case report and literature review. [PDF]

BMC Pediatr
Liu X, Han Y, Huang M, Fu T, Geng L.
europepmc   +1 more source